October 24, 2022

New York Facility to Fulfill U.S. and Canadian Orders

SAN RAMON, Calif., October 24, 2022—To provide faster delivery to eye care professionals and their patients, CooperVision has expanded its made-to-order manufacturing at its technologically advanced facility in Scottsville, N.Y. to include all Biofinity® toric multifocal contact lenses for the U.S. and Canada. All trial lenses and six-packs of the brand’s most prescribed powers are now being produced at the site, with plans to manufacture 100% of the U.S. and Canada’s Biofinity® toric multifocal six-pack volume within the next few months. The expansion reduces delivery times by eliminating international shipping and customs clearance steps.

All orders to service other markets will continue to be manufactured at the company’s facility in the U.K.

“The process of manufacturing a contact lens that corrects for both astigmatism and presbyopia is complex, and even more so when the available prescription options are so incredibly broad,” said Doug Brayer, Director of Marketing, Frequent Replacement Brands, CooperVision. “CooperVision’s continuous innovation and investment in manufacturing has not only made lenses like Biofinity® toric multifocal possible, but also enables us to deliver practitioners and patients a highly customized product on an expedited timeline.”

With CooperVision’s made-to-order advantage, Biofinity® toric multifocal lenses are available in more than 205,000 unique prescription options1 to ensure that eye care professionals have a lens for every patient. When using CooperVision’s OptiExpert app or the fitting guide, Biofinity® toric multifocal has a 93% success rate on initial fitting to save chair time for both ECPs and patients.2

CooperVision Biofinity® toric multifocal combines the comfort and proven optical designs of Biofinity® toric—the most prescribed toric lens on the market3—and Biofinity® multifocal, which has also earned the trust of ECPs and wearers alike. Like all Biofinity® silicone hydrogel lenses, Biofinity® toric multifocal features CooperVision’s Aquaform® Technology, which offers superb breathability and higher moisture content to keep eyes comfortable and healthy.

 

# # #

 

1 CVI data on file, 2019. Based on total number of prescription option combinations (for sphere, cylinder, axis and add - including D & N combinations) manufactured.

2 CVI Data on file 2018. Non-dispensing, subject masked, randomized, bilateral, cross-over short-term clinical evaluation. 27 astigmatic, presbyopic soft CL wearers at 2 sites (UK & US) fitted using CVI fit guide.

3 CVI data on file, 2021. US industry reports and internal estimates.

About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies, and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com

Media Contact
Heather Kowalczyk, APR, McDougall Communications for CooperVision
heather@mcdougallpr.com or (585) 434-2148